A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

NCT04777175 · tracked via the Priya Life Science China tracker

Sponsor

Yongchang Zhang

Phase

Observational

Started

2023-01-01

Last updated

2024-09-19

Condition(s) studied

Non Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

immunity therapy

immunity therapy: The patient receives immunotherapy

Study summary

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * 1.Diagnosed as advanced non-small cell lung cancer * 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation Exclusion Criteria: * The patient is diagnosed with small cell lung cancer

Primary outcome measure(s)

PFS — January 2021- January 2021 (1 year)
Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Trial sites (2)

Facility	City	Region	Status
Hunan Cancer Hospital	Changsha	Hunan	Recruiting
Hunan Cancer hospital	Changsha	Hunan	Recruiting

More Yongchang Zhang trials in China

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC Recruiting

Other trials for the same condition

A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China Active, not recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) Recruiting

NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC Starting soon

A Study of YL202 in Patients With Advanced Solid Tumors Recruiting

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04777175 on ClinicalTrials.gov ↗ ← All trials in China